Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23228610 | 0.91 | HTR2C (0.58) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL23210025 | 0.89 | HTR2C (0.59) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL30493303 | 0.82 | HTR2C (0.72) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23228761 | 0.81 | CHRNB2 (0.47) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23228757 | 0.77 | SLC6A4 (0.49) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23228747 | 0.77 | HTR2C (0.55) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL28452283 | 0.74 | HTR2C (0.52) | HTR2C | |
| SCHEMBL25985252 | 0.74 | HTR2C (0.41) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28003145 | 0.74 | KDM1A (0.46) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL13116599 | 0.74 | CHRNB4 (0.41) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |